The increased expression of the CYP2E1 and CYP4A11 genes in steatosis, with a down-regulation of the CYP2E1 P450 and elevated CYP4A11 in the progression of MASLD indicate the differential role of these genes. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatotic liver disease.